NCT07749651招募中1 期
A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults
Guangdong Hengrui Pharmaceutical Co., Ltd2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2026年8月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Safety and tolerability : Incidence and severity of any adverse events
研究概览
简要总结
A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The age of signing the informed consent form was between 18 and 55 years old (inclusive), both male and female.
- •Body weight ≥50 kg for men and ≥45 kg for women during the screening period, body mass index (BMI = weight (kg)/ height 2(m2)) between 19.0 and 26.0 kg/m2 (including boundary value)
- •Female participants of childbearing potential and male participants whose partners were fertile women had no plans to give birth, sperm or egg donation within 6 months after signing the informed consent, and voluntarily took highly effective contraceptive methods. Female participants of childbearing potential had to have a serum pregnancy test with a negative result during the screening and baseline periods
- •Female participants: not pregnant or lactatin
- •Before the trial, the participants had understood the nature, significance, possible benefits, possible inconvenience, potential risks and discomfort of the trial in detail, were able to understand the procedures and methods of the study, were willing to strictly abide by the requirements of the entire clinical study, and voluntarily signed informed consent
排除标准
- •Patients with previous or current clinical acute or chronic diseases of the circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry, or metabolic disorders, who were judged by the investigator to be unsuitable for enrollment
- •Patients had a history of severe herpesvirus infection, a history of malignancy, or current active infection
- •Patients with chronic or recurrent infection requiring treatment within 12 months before screening
- •A screening test for tuberculosis infection (interferon-γ release assay, IGRA) was positive
- •There was a previous history of risk factors for torsades de pointes
- •Patients who had undergone major surgery within 6 months before screening
- •Persons who had been vaccinated within 1 month before screening or planned to be vaccinated during the trial
- •Anyone who had taken any medication or health product (including Chinese herbal medicine) within 7 half-lives or 14 days before dose, whichever was longer, or who had known during the screening period that they might need to receive additional medication during the trial
- •Participants who had participated in a clinical trial and received a trial drug within 3 months before screening or who planned to participate in another clinical trial during the trial
- •Patients were screened if they had donated or lost at least 400 mL of blood (except physiological blood loss in women) within 3 months before the trial, received a transfusion or used blood products, or were planning to donate blood during or within 1 month after the trial
- •People who have special dietary requirements and cannot follow a uniform diet
- •Those with a history of drug abuse, drug use, or a positive screening test for drug abuse
- •Those who have difficulty in venous blood collection/cannot tolerate venipuncture, or have a history of fainting or fainting
- •If the site of administration was abnormal, the investigator judged that subcutaneous administration was not suitable
- •Participants may have been unable to complete the study for other reasons or may have been deemed by the investigator to be unsuitable for enrollment
研究组 & 干预措施
Treatment group 5: Dose5 Injection of SHR-7012 or placebo
Experimental
干预措施: SHR-7012 injection ; placebo ; (Drug)
Treatment group 1: Dose1 Injection of SHR-7012 or placebo
Experimental
干预措施: SHR-7012 injection ; placebo (Drug)
Treatment group 2: Dose2 Injection of SHR-7012 or placebo
Experimental
干预措施: SHR-7012 injection ; placebo (Drug)
Treatment group 3: Dose3 Injection of SHR-7012 or placebo
Experimental
干预措施: SHR-7012 injection ; placebo (Drug)
Treatment group 4: Dose4 Injection of SHR-7012 or placebo
Experimental
干预措施: SHR-7012 injection ; placebo (Drug)
结局指标
主要结局
Safety and tolerability : Incidence and severity of any adverse events
时间窗: Evaluation was performed up to Day141
次要结局
- AUC0 ∞(Evaluation was performed up to Day113 or Day141)
- Tmax(Evaluation was performed up to Day113 or Day141)
- Cmax(Evaluation was performed up to Day113 or Day141)
- t1/2(Evaluation was performed up to Day113 or Day141)
- λz(Evaluation was performed up to Day113 or Day141)
- CL/F(Evaluation was performed up to Day113 or Day141.)
- Vz/F(Evaluation was performed up to Day113 or Day141.)
- AUC0-t(Evaluation was performed up to Day113 or Day141)
- MRT0-t(Evaluation was performed up to Day113 or Day141.)
- MRT0-∞(Evaluation was performed up to Day113 or Day141.)
- AUC%Extrap(Evaluation was performed up to Day113 or Day141.)
- Antidrug antibody (ADA)(Evaluation was performed up to Day113 or Day141.)
- Neutralizing antibody (NAb)(Evaluation was performed up to Day113 or Day141.)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Trial of HRS-3095 in Healthy VolunteersChronic Spontaneous UrticariaNCT07686484Atridia Pty Ltd.36
招募中
1 期
A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid TumorsSolid TumorNCT07676903Suzhou Suncadia Biopharmaceuticals Co., Ltd.170
Unknown
1 期
健康受试者单次静脉或皮下给予 SHR-2106 后的安全性、耐受性、药代动力学和药效学 I 期临床研究ChiCTR2300073564广东恒瑞医药有限公司
Unknown
1 期
健康受试者单次皮下注射 SHR-1894 后的安全性、耐受性、 药代动力学和药效学——随机、双盲、安慰剂对照的 I 期临床研究ChiCTR2600120084苏州盛迪亚生物医药有限公司40
招募中
1 期
A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney FunctionNCT07322016Shandong Suncadia Medicine Co., Ltd.36